Carregant...
Rituximab Exhibits Altered Pharmacokinetics in Patients with Membranous Nephropathy
BACKGROUND: Rituximab (RTX) is a chimeric monoclonal anti-CD20 antibody used off-label in the treatment of membranous nephropathy (MN). Unfortunately, limited information is available on the pharmacokinetics of therapeutic proteins such as RTX in patients with glomerular kidney diseases. OBJECTIVE:...
Guardat en:
| Publicat a: | Ann Pharmacother |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6629258/ https://ncbi.nlm.nih.gov/pubmed/30293439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1060028018803587 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|